Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Anti-Aquaporin-4 Igg in Patients Presenting With Unilateral Optic Neuritis: A Cohort Study



Etemadifar M1, 2, 3 ; Abtahi MA3, 4, 5 ; Razmjoo H3, 5 ; Abtahi SH1, 3, 4 ; Dehghani AR3, 5 ; Abtahi ZA3, 4, 5 ; Akbari M3 ; Mazaheri S6 ; Maghzi AH1, 3, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Isfahan Research Committee of Multiple Sclerosis (IRCOMS), Isfahan, Iran
  2. 2. Department of Neurology, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Medical School, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Medical Students' Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Department of Ophtalmology, Feiz Eye Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
  6. 6. Hamadan University of Medical Sciences, Hamadan, Iran
  7. 7. Neuroimmunology Unit, Center for Neuroscience and Trauma, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, United Kingdom

Source: International Journal of Preventive Medicine Published:2012

Abstract

Background: Optic neuritis (ON) can be the first presentation of multiple sclerosis (MS) or neuromyelitis optica (NMO). Anti-aquaporin-4 IgG (AQP4 IgG) is a highly specific and moderately sensitive biomarker for NMO. This study was designed to assess the rate of seropositivity for AQP4 IgG, and the short-term outcome of patients presenting with single isolated ON (SION). Methods: A cohort of 41 consecutive patients experiencing severe (< 20 / 200) SION (not fulfilling the diagnostic criteria for MS or NMO), was prospectively recruited. Blood sampling was carried out immediately after the diagnosis of ON, and AQP4 IgG was tested qualitatively, using an indirect immunofluorescence kit. After clinical and paraclinical investigations, all the patients were followed up for a short-term period of at least 18 months. Results: The seroprevalence among the initial ON patients was 9.7% (4 / 41). The short-term conversion rate to MS and NMO was estimated to be about 7.3 and 4.9%, respectively. The conversion rate to NMO in initially seropositive patients was greater than that for the whole cohort [2 / 4 (50%) vs. 2 / 41 (4.9%); P = 0.035; Odds ratio: 19.5, 95% confidence interval: 1.73 to 219.50]. Conclusion: AQP4 IgG seropositive SION patients were more likely to develop NMO in comparison to the total SION population. Further studies, with a longer follow-up period and larger sample sizes are warranted to assess the clinical and prognostic value of assessing AQP4 IgG in SION.
Other Related Docs
11. Retinal Optical Coherence Tomography in Neuromyelitis Optica, Neurology: Neuroimmunology and NeuroInflammation (2021)
19. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)
21. Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders, Neurology: Neuroimmunology and NeuroInflammation (2024)
25. Whole Spinal Transverse Myelitis in Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis and Related Disorders (2024)
27. Frequency of Diencephalic Syndrome in Nmosd, Acta Neurologica Belgica (2022)
42. Mri Signs of Cns Demyelinating Diseases, Multiple Sclerosis and Related Disorders (2021)
46. Color Blindness Among Multiple Sclerosis Patients in Isfahan, Journal of Research in Medical Sciences (2012)